Piper Sandler Initiates Coverage On Turnstone Biologics with Overweight Rating, Announces Price Target of $20
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Joseph Catanzaro has initiated coverage on Turnstone Biologics (NASDAQ:TSBX) with an Overweight rating and a price target of $20.
August 15, 2023 | 9:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Turnstone Biologics with an Overweight rating and a price target of $20.
The initiation of coverage by Piper Sandler with an Overweight rating indicates a positive outlook for Turnstone Biologics. The price target of $20 suggests potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100